Cherian, Christina
Appendino, Juan P. http://orcid.org/0000-0002-1112-7002
Ashtiani, Setareh
Federico, Paolo
Molnar, Christine P.
Kerr, Marina
Khan, Aneal
Au, Ping Yee Billie
Klein, Karl Martin http://orcid.org/0000-0002-6654-1665
Funding for this research was provided by:
hotchkiss brain institute, university of calgary (Startup funds)
alberta children's hospital research institute (Startup funds)
cumming school of medicine, university of calgary (Startup funds)
Article History
Received: 2 July 2021
Revised: 13 September 2021
Accepted: 14 September 2021
First Online: 19 September 2021
Declarations
:
: C. Cherian reports no disclosures relevant to the manuscript. J.P. Appendino reports personal and educational fees from UCB Pharma, PendoPharm Inc., and Sunovion Pharmaceuticals Inc. S. Ashtiani reports no disclosures relevant to the manuscript. P. Federico reports no disclosures relevant to the manuscript. C.P. Molnar reports no disclosures relevant to the manuscript. A. Khan and M. Kerr received part of the funding for the MITO-FIND project from MITOCANADA through the Alberta Children’s Hospital Research Foundation. P. Y. B. Au reports no disclosures relevant to the manuscript. K.M. Klein reports personal fees from UCB Pharma, Novartis Pharma AG, Eisai, and GW Pharmaceuticals, grants from the federal state Hessen, Germany, through the LOEWE program and from the Canadian Institutes of Health Research.
: The study was approved by the Conjoint Health Research Ethics Board at University of Calgary and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: All participants or their legal guardians provided written informed consent prior to inclusion in the study.
: The consent includes publication of de-identified health information.